Global Neurodegenerative Drugs Market Growth 2022-2028

1.1 Market Introduction

1.2 Years Considered

1.3 Research Objectives

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Executive Summary

2.1 World Market Overview

2.1.1 Global Neurodegenerative Drugs Annual Sales 2017-2028

2.1.2 World Current & Future Analysis for Neurodegenerative Drugs by Geographic Region, 2017, 2022 & 2028

2.1.3 World Current & Future Analysis for Neurodegenerative Drugs by Country/Region, 2017, 2022 & 2028

2.2 Neurodegenerative Drugs Segment by Type

2.2.1 NMDA

2.2.2 SSRIs

2.2.3 Dopamine Inhibitors

2.3 Neurodegenerative Drugs Sales by Type

2.3.1 Global Neurodegenerative Drugs Sales Market Share by Type (2017-2022)

2.3.2 Global Neurodegenerative Drugs Revenue and Market Share by Type (2017-2022)

2.3.3 Global Neurodegenerative Drugs Sale Price by Type (2017-2022)

2.4 Neurodegenerative Drugs Segment by Application

2.4.1 Parkinson’s Disease

2.4.2 Huntington Disease

2.4.3 Amyotrophic Lateral Sclerosis

2.4.4 Alzheimer’s Disease

2.5 Neurodegenerative Drugs Sales by Application

2.5.1 Global Neurodegenerative Drugs Sale Market Share by Application (2017-2022)

2.5.2 Global Neurodegenerative Drugs Revenue and Market Share by Application (2017-2022)

2.5.3 Global Neurodegenerative Drugs Sale Price by Application (2017-2022)

3 Global Neurodegenerative Drugs by Company

3.1 Global Neurodegenerative Drugs Breakdown Data by Company

3.1.1 Global Neurodegenerative Drugs Annual Sales by Company (2020-2022)

3.1.2 Global Neurodegenerative Drugs Sales Market Share by Company (2020-2022)

3.2 Global Neurodegenerative Drugs Annual Revenue by Company (2020-2022)

3.2.1 Global Neurodegenerative Drugs Revenue by Company (2020-2022)

3.2.2 Global Neurodegenerative Drugs Revenue Market Share by Company (2020-2022)

3.3 Global Neurodegenerative Drugs Sale Price by Company

3.4 Key Manufacturers Neurodegenerative Drugs Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Neurodegenerative Drugs Product Location Distribution

3.4.2 Players Neurodegenerative Drugs Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Neurodegenerative Drugs by Geographic Region

4.1 World Historic Neurodegenerative Drugs Market Size by Geographic Region (2017-2022)

4.1.1 Global Neurodegenerative Drugs Annual Sales by Geographic Region (2017-2022)

4.1.2 Global Neurodegenerative Drugs Annual Revenue by Geographic Region

4.2 World Historic Neurodegenerative Drugs Market Size by Country/Region (2017-2022)

4.2.1 Global Neurodegenerative Drugs Annual Sales by Country/Region (2017-2022)

4.2.2 Global Neurodegenerative Drugs Annual Revenue by Country/Region

4.3 Americas Neurodegenerative Drugs Sales Growth

4.4 APAC Neurodegenerative Drugs Sales Growth

4.5 Europe Neurodegenerative Drugs Sales Growth

4.6 Middle East & Africa Neurodegenerative Drugs Sales Growth

5 Americas

5.1 Americas Neurodegenerative Drugs Sales by Country

5.1.1 Americas Neurodegenerative Drugs Sales by Country (2017-2022)

5.1.2 Americas Neurodegenerative Drugs Revenue by Country (2017-2022)

5.2 Americas Neurodegenerative Drugs Sales by Type

5.3 Americas Neurodegenerative Drugs Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Neurodegenerative Drugs Sales by Region

6.1.1 APAC Neurodegenerative Drugs Sales by Region (2017-2022)

6.1.2 APAC Neurodegenerative Drugs Revenue by Region (2017-2022)

6.2 APAC Neurodegenerative Drugs Sales by Type

6.3 APAC Neurodegenerative Drugs Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 Europe

7.1 Europe Neurodegenerative Drugs by Country

7.1.1 Europe Neurodegenerative Drugs Sales by Country (2017-2022)

7.1.2 Europe Neurodegenerative Drugs Revenue by Country (2017-2022)

7.2 Europe Neurodegenerative Drugs Sales by Type

7.3 Europe Neurodegenerative Drugs Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 Middle East & Africa

8.1 Middle East & Africa Neurodegenerative Drugs by Country

8.1.1 Middle East & Africa Neurodegenerative Drugs Sales by Country (2017-2022)

8.1.2 Middle East & Africa Neurodegenerative Drugs Revenue by Country (2017-2022)

8.2 Middle East & Africa Neurodegenerative Drugs Sales by Type

8.3 Middle East & Africa Neurodegenerative Drugs Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 Market Drivers, Challenges and Trends

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Neurodegenerative Drugs

10.3 Manufacturing Process Analysis of Neurodegenerative Drugs

10.4 Industry Chain Structure of Neurodegenerative Drugs

11 Marketing, Distributors and Customer

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Neurodegenerative Drugs Distributors

11.3 Neurodegenerative Drugs Customer

12 World Forecast Review for Neurodegenerative Drugs by Geographic Region

12.1 Global Neurodegenerative Drugs Market Size Forecast by Region

12.1.1 Global Neurodegenerative Drugs Forecast by Region (2023-2028)

12.1.2 Global Neurodegenerative Drugs Annual Revenue Forecast by Region (2023-2028)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Neurodegenerative Drugs Forecast by Type

12.7 Global Neurodegenerative Drugs Forecast by Application

13 Key Players Analysis

13.1 Novartis

13.1.1 Novartis Company Information

13.1.2 Novartis Neurodegenerative Drugs Product Offered

13.1.3 Novartis Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.1.4 Novartis Main Business Overview

13.1.5 Novartis Latest Developments

13.2 Pfizer

13.2.1 Pfizer Company Information

13.2.2 Pfizer Neurodegenerative Drugs Product Offered

13.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.2.4 Pfizer Main Business Overview

13.2.5 Pfizer Latest Developments

13.3 Merck Serono

13.3.1 Merck Serono Company Information

13.3.2 Merck Serono Neurodegenerative Drugs Product Offered

13.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.3.4 Merck Serono Main Business Overview

13.3.5 Merck Serono Latest Developments

13.4 Biogen Idec

13.4.1 Biogen Idec Company Information

13.4.2 Biogen Idec Neurodegenerative Drugs Product Offered

13.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.4.4 Biogen Idec Main Business Overview

13.4.5 Biogen Idec Latest Developments

13.5 TEVA

13.5.1 TEVA Company Information

13.5.2 TEVA Neurodegenerative Drugs Product Offered

13.5.3 TEVA Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.5.4 TEVA Main Business Overview

13.5.5 TEVA Latest Developments

13.6 UCB

13.6.1 UCB Company Information

13.6.2 UCB Neurodegenerative Drugs Product Offered

13.6.3 UCB Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.6.4 UCB Main Business Overview

13.6.5 UCB Latest Developments

13.7 Boehringer Ingelheim

13.7.1 Boehringer Ingelheim Company Information

13.7.2 Boehringer Ingelheim Neurodegenerative Drugs Product Offered

13.7.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.7.4 Boehringer Ingelheim Main Business Overview

13.7.5 Boehringer Ingelheim Latest Developments

13.8 Sanofi

13.8.1 Sanofi Company Information

13.8.2 Sanofi Neurodegenerative Drugs Product Offered

13.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.8.4 Sanofi Main Business Overview

13.8.5 Sanofi Latest Developments

13.9 GlaxoSmithKline

13.9.1 GlaxoSmithKline Company Information

13.9.2 GlaxoSmithKline Neurodegenerative Drugs Product Offered

13.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.9.4 GlaxoSmithKline Main Business Overview

13.9.5 GlaxoSmithKline Latest Developments

13.10 Livzon Pharmaceutical

13.10.1 Livzon Pharmaceutical Company Information

13.10.2 Livzon Pharmaceutical Neurodegenerative Drugs Product Offered

13.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.10.4 Livzon Pharmaceutical Main Business Overview

13.10.5 Livzon Pharmaceutical Latest Developments

13.11 Haisco Pharmaceutical

13.11.1 Haisco Pharmaceutical Company Information

13.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Product Offered

13.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.11.4 Haisco Pharmaceutical Main Business Overview

13.11.5 Haisco Pharmaceutical Latest Developments

13.12 Jingxin Pharmaceutical

13.12.1 Jingxin Pharmaceutical Company Information

13.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Product Offered

13.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.12.4 Jingxin Pharmaceutical Main Business Overview

13.12.5 Jingxin Pharmaceutical Latest Developments

13.13 Dongcheng Biochemicals

13.13.1 Dongcheng Biochemicals Company Information

13.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Product Offered

13.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.13.4 Dongcheng Biochemicals Main Business Overview

13.13.5 Dongcheng Biochemicals Latest Developments

13.14 Hisun Pharmaceutical

13.14.1 Hisun Pharmaceutical Company Information

13.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Product Offered

13.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.14.4 Hisun Pharmaceutical Main Business Overview

13.14.5 Hisun Pharmaceutical Latest Developments

13.15 Luye Pharma

13.15.1 Luye Pharma Company Information

13.15.2 Luye Pharma Neurodegenerative Drugs Product Offered

13.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.15.4 Luye Pharma Main Business Overview

13.15.5 Luye Pharma Latest Developments

13.16 Ark Pharmaceutical

13.16.1 Ark Pharmaceutical Company Information

13.16.2 Ark Pharmaceutical Neurodegenerative Drugs Product Offered

13.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.16.4 Ark Pharmaceutical Main Business Overview

13.16.5 Ark Pharmaceutical Latest Developments

13.17 Kanghong Pharmaceutical

13.17.1 Kanghong Pharmaceutical Company Information

13.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Product Offered

13.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.17.4 Kanghong Pharmaceutical Main Business Overview

13.17.5 Kanghong Pharmaceutical Latest Developments

13.18 Huahai Pharmaceutical

13.18.1 Huahai Pharmaceutical Company Information

13.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Product Offered

13.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.18.4 Huahai Pharmaceutical Main Business Overview

13.18.5 Huahai Pharmaceutical Latest Developments

13.19 BORA PHARMACEUTICALS

13.19.1 BORA PHARMACEUTICALS Company Information

13.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Offered

13.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue, Price and Gross Margin (2020-2022)

13.19.4 BORA PHARMACEUTICALS Main Business Overview

13.19.5 BORA PHARMACEUTICALS Latest Developments

14 Research Findings and Conclusion

Table 1. Neurodegenerative Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)

Table 2. Neurodegenerative Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)

Table 3. Major Players of NMDA

Table 4. Major Players of SSRIs

Table 5. Major Players of Dopamine Inhibitors

Table 6. Global Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)

Table 7. Global Neurodegenerative Drugs Sales Market Share by Type (2017-2022)

Table 8. Global Neurodegenerative Drugs Revenue by Type (2017-2022) & ($ million)

Table 9. Global Neurodegenerative Drugs Revenue Market Share by Type (2017-2022)

Table 10. Global Neurodegenerative Drugs Sale Price by Type (2017-2022) & (US$/Unit)

Table 11. Global Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)

Table 12. Global Neurodegenerative Drugs Sales Market Share by Application (2017-2022)

Table 13. Global Neurodegenerative Drugs Revenue by Application (2017-2022)

Table 14. Global Neurodegenerative Drugs Revenue Market Share by Application (2017-2022)

Table 15. Global Neurodegenerative Drugs Sale Price by Application (2017-2022) & (US$/Unit)

Table 16. Global Neurodegenerative Drugs Sales by Company (2020-2022) & (K Units)

Table 17. Global Neurodegenerative Drugs Sales Market Share by Company (2020-2022)

Table 18. Global Neurodegenerative Drugs Revenue by Company (2020-2022) ($ Millions)

Table 19. Global Neurodegenerative Drugs Revenue Market Share by Company (2020-2022)

Table 20. Global Neurodegenerative Drugs Sale Price by Company (2020-2022) & (US$/Unit)

Table 21. Key Manufacturers Neurodegenerative Drugs Producing Area Distribution and Sales Area

Table 22. Players Neurodegenerative Drugs Products Offered

Table 23. Neurodegenerative Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Neurodegenerative Drugs Sales by Geographic Region (2017-2022) & (K Units)

Table 27. Global Neurodegenerative Drugs Sales Market Share Geographic Region (2017-2022)

Table 28. Global Neurodegenerative Drugs Revenue by Geographic Region (2017-2022) & ($ millions)

Table 29. Global Neurodegenerative Drugs Revenue Market Share by Geographic Region (2017-2022)

Table 30. Global Neurodegenerative Drugs Sales by Country/Region (2017-2022) & (K Units)

Table 31. Global Neurodegenerative Drugs Sales Market Share by Country/Region (2017-2022)

Table 32. Global Neurodegenerative Drugs Revenue by Country/Region (2017-2022) & ($ millions)

Table 33. Global Neurodegenerative Drugs Revenue Market Share by Country/Region (2017-2022)

Table 34. Americas Neurodegenerative Drugs Sales by Country (2017-2022) & (K Units)

Table 35. Americas Neurodegenerative Drugs Sales Market Share by Country (2017-2022)

Table 36. Americas Neurodegenerative Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 37. Americas Neurodegenerative Drugs Revenue Market Share by Country (2017-2022)

Table 38. Americas Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)

Table 39. Americas Neurodegenerative Drugs Sales Market Share by Type (2017-2022)

Table 40. Americas Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)

Table 41. Americas Neurodegenerative Drugs Sales Market Share by Application (2017-2022)

Table 42. APAC Neurodegenerative Drugs Sales by Region (2017-2022) & (K Units)

Table 43. APAC Neurodegenerative Drugs Sales Market Share by Region (2017-2022)

Table 44. APAC Neurodegenerative Drugs Revenue by Region (2017-2022) & ($ Millions)

Table 45. APAC Neurodegenerative Drugs Revenue Market Share by Region (2017-2022)

Table 46. APAC Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)

Table 47. APAC Neurodegenerative Drugs Sales Market Share by Type (2017-2022)

Table 48. APAC Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)

Table 49. APAC Neurodegenerative Drugs Sales Market Share by Application (2017-2022)

Table 50. Europe Neurodegenerative Drugs Sales by Country (2017-2022) & (K Units)

Table 51. Europe Neurodegenerative Drugs Sales Market Share by Country (2017-2022)

Table 52. Europe Neurodegenerative Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 53. Europe Neurodegenerative Drugs Revenue Market Share by Country (2017-2022)

Table 54. Europe Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)

Table 55. Europe Neurodegenerative Drugs Sales Market Share by Type (2017-2022)

Table 56. Europe Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)

Table 57. Europe Neurodegenerative Drugs Sales Market Share by Application (2017-2022)

Table 58. Middle East & Africa Neurodegenerative Drugs Sales by Country (2017-2022) & (K Units)

Table 59. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Country (2017-2022)

Table 60. Middle East & Africa Neurodegenerative Drugs Revenue by Country (2017-2022) & ($ Millions)

Table 61. Middle East & Africa Neurodegenerative Drugs Revenue Market Share by Country (2017-2022)

Table 62. Middle East & Africa Neurodegenerative Drugs Sales by Type (2017-2022) & (K Units)

Table 63. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Type (2017-2022)

Table 64. Middle East & Africa Neurodegenerative Drugs Sales by Application (2017-2022) & (K Units)

Table 65. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Application (2017-2022)

Table 66. Key Market Drivers & Growth Opportunities of Neurodegenerative Drugs

Table 67. Key Market Challenges & Risks of Neurodegenerative Drugs

Table 68. Key Industry Trends of Neurodegenerative Drugs

Table 69. Neurodegenerative Drugs Raw Material

Table 70. Key Suppliers of Raw Materials

Table 71. Neurodegenerative Drugs Distributors List

Table 72. Neurodegenerative Drugs Customer List

Table 73. Global Neurodegenerative Drugs Sales Forecast by Region (2023-2028) & (K Units)

Table 74. Global Neurodegenerative Drugs Sales Market Forecast by Region

Table 75. Global Neurodegenerative Drugs Revenue Forecast by Region (2023-2028) & ($ millions)

Table 76. Global Neurodegenerative Drugs Revenue Market Share Forecast by Region (2023-2028)

Table 77. Americas Neurodegenerative Drugs Sales Forecast by Country (2023-2028) & (K Units)

Table 78. Americas Neurodegenerative Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 79. APAC Neurodegenerative Drugs Sales Forecast by Region (2023-2028) & (K Units)

Table 80. APAC Neurodegenerative Drugs Revenue Forecast by Region (2023-2028) & ($ millions)

Table 81. Europe Neurodegenerative Drugs Sales Forecast by Country (2023-2028) & (K Units)

Table 82. Europe Neurodegenerative Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 83. Middle East & Africa Neurodegenerative Drugs Sales Forecast by Country (2023-2028) & (K Units)

Table 84. Middle East & Africa Neurodegenerative Drugs Revenue Forecast by Country (2023-2028) & ($ millions)

Table 85. Global Neurodegenerative Drugs Sales Forecast by Type (2023-2028) & (K Units)

Table 86. Global Neurodegenerative Drugs Sales Market Share Forecast by Type (2023-2028)

Table 87. Global Neurodegenerative Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)

Table 88. Global Neurodegenerative Drugs Revenue Market Share Forecast by Type (2023-2028)

Table 89. Global Neurodegenerative Drugs Sales Forecast by Application (2023-2028) & (K Units)

Table 90. Global Neurodegenerative Drugs Sales Market Share Forecast by Application (2023-2028)

Table 91. Global Neurodegenerative Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)

Table 92. Global Neurodegenerative Drugs Revenue Market Share Forecast by Application (2023-2028)

Table 93. Novartis Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 94. Novartis Neurodegenerative Drugs Product Offered

Table 95. Novartis Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 96. Novartis Main Business

Table 97. Novartis Latest Developments

Table 98. Pfizer Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 99. Pfizer Neurodegenerative Drugs Product Offered

Table 100. Pfizer Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 101. Pfizer Main Business

Table 102. Pfizer Latest Developments

Table 103. Merck Serono Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 104. Merck Serono Neurodegenerative Drugs Product Offered

Table 105. Merck Serono Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 106. Merck Serono Main Business

Table 107. Merck Serono Latest Developments

Table 108. Biogen Idec Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 109. Biogen Idec Neurodegenerative Drugs Product Offered

Table 110. Biogen Idec Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 111. Biogen Idec Main Business

Table 112. Biogen Idec Latest Developments

Table 113. TEVA Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 114. TEVA Neurodegenerative Drugs Product Offered

Table 115. TEVA Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 116. TEVA Main Business

Table 117. TEVA Latest Developments

Table 118. UCB Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 119. UCB Neurodegenerative Drugs Product Offered

Table 120. UCB Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 121. UCB Main Business

Table 122. UCB Latest Developments

Table 123. Boehringer Ingelheim Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 124. Boehringer Ingelheim Neurodegenerative Drugs Product Offered

Table 125. Boehringer Ingelheim Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 126. Boehringer Ingelheim Main Business

Table 127. Boehringer Ingelheim Latest Developments

Table 128. Sanofi Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 129. Sanofi Neurodegenerative Drugs Product Offered

Table 130. Sanofi Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 131. Sanofi Main Business

Table 132. Sanofi Latest Developments

Table 133. GlaxoSmithKline Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 134. GlaxoSmithKline Neurodegenerative Drugs Product Offered

Table 135. GlaxoSmithKline Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 136. GlaxoSmithKline Main Business

Table 137. GlaxoSmithKline Latest Developments

Table 138. Livzon Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 139. Livzon Pharmaceutical Neurodegenerative Drugs Product Offered

Table 140. Livzon Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 141. Livzon Pharmaceutical Main Business

Table 142. Livzon Pharmaceutical Latest Developments

Table 143. Haisco Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 144. Haisco Pharmaceutical Neurodegenerative Drugs Product Offered

Table 145. Haisco Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 146. Haisco Pharmaceutical Main Business

Table 147. Haisco Pharmaceutical Latest Developments

Table 148. Jingxin Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 149. Jingxin Pharmaceutical Neurodegenerative Drugs Product Offered

Table 150. Jingxin Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 151. Jingxin Pharmaceutical Main Business

Table 152. Jingxin Pharmaceutical Latest Developments

Table 153. Dongcheng Biochemicals Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 154. Dongcheng Biochemicals Neurodegenerative Drugs Product Offered

Table 155. Dongcheng Biochemicals Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 156. Dongcheng Biochemicals Main Business

Table 157. Dongcheng Biochemicals Latest Developments

Table 158. Hisun Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 159. Hisun Pharmaceutical Neurodegenerative Drugs Product Offered

Table 160. Hisun Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 161. Hisun Pharmaceutical Main Business

Table 162. Hisun Pharmaceutical Latest Developments

Table 163. Luye Pharma Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 164. Luye Pharma Neurodegenerative Drugs Product Offered

Table 165. Luye Pharma Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 166. Luye Pharma Main Business

Table 167. Luye Pharma Latest Developments

Table 168. Ark Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 169. Ark Pharmaceutical Neurodegenerative Drugs Product Offered

Table 170. Ark Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 171. Ark Pharmaceutical Main Business

Table 172. Ark Pharmaceutical Latest Developments

Table 173. Kanghong Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 174. Kanghong Pharmaceutical Neurodegenerative Drugs Product Offered

Table 175. Kanghong Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 176. Kanghong Pharmaceutical Main Business

Table 177. Kanghong Pharmaceutical Latest Developments

Table 178. Huahai Pharmaceutical Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 179. Huahai Pharmaceutical Neurodegenerative Drugs Product Offered

Table 180. Huahai Pharmaceutical Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 181. Huahai Pharmaceutical Main Business

Table 182. Huahai Pharmaceutical Latest Developments

Table 183. BORA PHARMACEUTICALS Basic Information, Neurodegenerative Drugs Manufacturing Base, Sales Area and Its Competitors

Table 184. BORA PHARMACEUTICALS Neurodegenerative Drugs Product Offered

Table 185. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)

Table 186. BORA PHARMACEUTICALS Main Business

Table 187. BORA PHARMACEUTICALS Latest Developments

List of Figures

Figure 1. Picture of Neurodegenerative Drugs

Figure 2. Neurodegenerative Drugs Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Neurodegenerative Drugs Sales Growth Rate 2017-2028 (K Units)

Figure 7. Global Neurodegenerative Drugs Revenue Growth Rate 2017-2028 ($ Millions)

Figure 8. Neurodegenerative Drugs Sales by Region (2021 & 2028) & ($ millions)

Figure 9. Product Picture of NMDA

Figure 10. Product Picture of SSRIs

Figure 11. Product Picture of Dopamine Inhibitors

Figure 12. Global Neurodegenerative Drugs Sales Market Share by Type in 2021

Figure 13. Global Neurodegenerative Drugs Revenue Market Share by Type (2017-2022)

Figure 14. Neurodegenerative Drugs Consumed in Parkinson’s Disease

Figure 15. Global Neurodegenerative Drugs Market: Parkinson’s Disease (2017-2022) & (K Units)

Figure 16. Neurodegenerative Drugs Consumed in Huntington Disease

Figure 17. Global Neurodegenerative Drugs Market: Huntington Disease (2017-2022) & (K Units)

Figure 18. Neurodegenerative Drugs Consumed in Amyotrophic Lateral Sclerosis

Figure 19. Global Neurodegenerative Drugs Market: Amyotrophic Lateral Sclerosis (2017-2022) & (K Units)

Figure 20. Neurodegenerative Drugs Consumed in Alzheimer’s Disease

Figure 21. Global Neurodegenerative Drugs Market: Alzheimer’s Disease (2017-2022) & (K Units)

Figure 22. Global Neurodegenerative Drugs Sales Market Share by Application (2017-2022)

Figure 23. Global Neurodegenerative Drugs Revenue Market Share by Application in 2021

Figure 24. Neurodegenerative Drugs Revenue Market by Company in 2021 ($ Million)

Figure 25. Global Neurodegenerative Drugs Revenue Market Share by Company in 2021

Figure 26. Global Neurodegenerative Drugs Sales Market Share by Geographic Region (2017-2022)

Figure 27. Global Neurodegenerative Drugs Revenue Market Share by Geographic Region in 2021

Figure 28. Global Neurodegenerative Drugs Sales Market Share by Region (2017-2022)

Figure 29. Global Neurodegenerative Drugs Revenue Market Share by Country/Region in 2021

Figure 30. Americas Neurodegenerative Drugs Sales 2017-2022 (K Units)

Figure 31. Americas Neurodegenerative Drugs Revenue 2017-2022 ($ Millions)

Figure 32. APAC Neurodegenerative Drugs Sales 2017-2022 (K Units)

Figure 33. APAC Neurodegenerative Drugs Revenue 2017-2022 ($ Millions)

Figure 34. Europe Neurodegenerative Drugs Sales 2017-2022 (K Units)

Figure 35. Europe Neurodegenerative Drugs Revenue 2017-2022 ($ Millions)

Figure 36. Middle East & Africa Neurodegenerative Drugs Sales 2017-2022 (K Units)

Figure 37. Middle East & Africa Neurodegenerative Drugs Revenue 2017-2022 ($ Millions)

Figure 38. Americas Neurodegenerative Drugs Sales Market Share by Country in 2021

Figure 39. Americas Neurodegenerative Drugs Revenue Market Share by Country in 2021

Figure 40. United States Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 41. Canada Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 42. Mexico Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 43. Brazil Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 44. APAC Neurodegenerative Drugs Sales Market Share by Region in 2021

Figure 45. APAC Neurodegenerative Drugs Revenue Market Share by Regions in 2021

Figure 46. China Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 47. Japan Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 48. South Korea Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 49. Southeast Asia Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 50. India Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 51. Australia Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 52. Europe Neurodegenerative Drugs Sales Market Share by Country in 2021

Figure 53. Europe Neurodegenerative Drugs Revenue Market Share by Country in 2021

Figure 54. Germany Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 55. France Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 56. UK Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 57. Italy Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 58. Russia Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 59. Middle East & Africa Neurodegenerative Drugs Sales Market Share by Country in 2021

Figure 60. Middle East & Africa Neurodegenerative Drugs Revenue Market Share by Country in 2021

Figure 61. Egypt Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 62. South Africa Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 63. Israel Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 64. Turkey Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 65. GCC Country Neurodegenerative Drugs Revenue Growth 2017-2022 ($ Millions)

Figure 66. Manufacturing Cost Structure Analysis of Neurodegenerative Drugs in 2021

Figure 67. Manufacturing Process Analysis of Neurodegenerative Drugs

Figure 68. Industry Chain Structure of Neurodegenerative Drugs

Figure 69. Channels of Distribution

Figure 70. Distributors Profiles